Offer
- breast cancer high-risk test - monogenic*,
- breast cancer high-risk test - polygenic*,
- colon cancer high-risk test*,
- prostate cancer high-risk test*,
- test of moderately increased risk of malignancies of various sites*,
- test of significantly decreased risk of breast cancer*,
- test detecting inclusion criteria to clinical trial of cis-platin treatment for patients with cancer at various sites*,
- test detecting inclusion criteria to clinical trial of "inhibilator PARP" treatment for patients with overian cancer with BRCA1 mutation*,
- test detecting inclusion criteria to clinical trial of trabectedin treatment for patients with breast cancer with BRCA1 mutation*.
- consultation with prof. dr hab. n. med. Jan Lubiński,
- consultation with dr hab. n. med. Jacek Gronwald,
* At present test can be offered for all countries except of the US, Canada, Mexico and Australia.
